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Abstract
Drug safety issues pose serious health threats to the population and constitute a major cause of mortality worldwide. Due
to the prominent implications to both public health and the pharmaceutical industry, it is of great importance to unravel
the molecular mechanisms by which an adverse drug reaction can be potentially elicited. These mechanisms can be
investigated by placing the pharmaco-epidemiologically detected adverse drug reaction in an information-rich context and
by exploiting all currently available biomedical knowledge to substantiate it. We present a computational framework for the
biological annotation of potential adverse drug reactions. First, the proposed framework investigates previous evidences on
the drug-event association in the context of biomedical literature (signal filtering). Then, it seeks to provide a biological
explanation (signal substantiation) by exploring mechanistic connections that might explain why a drug produces a specific
adverse reaction. The mechanistic connections include the activity of the drug, related compounds and drug metabolites on
protein targets, the association of protein targets to clinical events, and the annotation of proteins (both protein targets and
proteins associated with clinical events) to biological pathways. Hence, the workflows for signal filtering and substantiation
integrate modules for literature and database mining, in silico drug-target profiling, and analyses based on gene-disease
networks and biological pathways. Application examples of these workflows carried out on selected cases of drug safety
signals are discussed. The methodology and workflows presented offer a novel approach to explore the molecular
mechanisms underlying adverse drug reactions.
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Introduction
Drug safety issues can arise during pre-clinical screening,
clinical trials and, more importantly, after the drug is marketed
and tested for the first time on the population [1]. Although
relatively rare once a drug is marketed, drug safety issues
constitute a major cause of morbidity and mortality worldwide.
In 1998, Lazarou et al estimated that yearly about 2 million
patients in the US are affected by a serious adverse drug reactions
(ADRs) resulting in approximately 100 000 fatalities, ranking ADRs
between the fourth and sixth cause of death in the US, not far
behind cancer and heart diseases [2]. Similar figures were estimated
more recently for other western countries [3,4,5]. Serious ADRs
resulting from the treatment with thalidomide prompted modern
drug legislation more than 40 years ago [6]. Over the past 10 years,
19 broadly used marketed drugs were withdrawn after presenting
unexpected side effects [1,3]. The current and future challenges of
drug development and drug utilization, and a number of recent
high-impact drug safety issues (e.g. rofecoxib) highlight the need of
an improvement of safety monitoring systems [5]. In this regard,
initiatives such as the EC-funded EU-ADR project seek to develop
methodologies to improve the way drug safety signals are detected
and analyzed [7,8].
Due to the important implications of an ADR in both public
health and the pharmaceutical industry, unraveling the molecular
mechanisms by which the ADR is elicited is of great relevance.
Understanding the molecular mechanisms of ADRs can be
achieved by placing the drug adverse reaction in the context of
current biomedical knowledge that might explain it. Due to the
huge amounts of data generated by the ‘‘omics’’ experiments, and
the ever-increasing volume of data and knowledge stored in
databases related with ADRs, the application of bioinformatics
analysis tools is essential in order to study and analyze the
molecular and biological basis of ADRs.
ADR mechanisms
Although the factors that determine the susceptibility to ADRs
are not completely well understood, accumulating evidence over
the years indicate an important role of genetic factors [9]. ADRs
can be mechanistically related to drug metabolism phenomena,
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leading for instance to an unusual drug accumulation in the body
[9]. They can be associated with inter-individual genetic variants,
most notably single nucleotide polymorphisms (SNPs), in genes
encoding drug metabolizing enzymes and drug target genes [9].
One of the first ADRs explained by a genetic factor was the
inherited deficiency of the enzyme glucose-6-phosphate dehydro-
genase causing severe anemia in patients treated with the
antimalarial drug primaquine [10]. Alternatively, an ADR can
be caused by the interaction of the drug with a target different
from the originally intended target (also known as off-targets) [11].
A well-known example of an off-target ADR is provided by
aspirin, whose anti-inflammatory effect, exerted by inhibition of
prostaglandin production by COX-2, comes at the expense of
irritation of the stomach mucosa by its unintended inhibition of
COX-1 [12,13]. Furthermore, in addition to mechanisms related
to off-target pharmacology, it is becoming evident that ADRs may
often be caused by the combined action of multiple genes [9]. The
anticoagulant warfarin, which shows a varying degree of
anticoagulant effects, is often associated with hemorrhages, and
leads the list of drugs with serious ADR in the US and Europe [9].
A 50% of the variable effects of warfarin are explained by
polymorphisms in the genes CYP2C9 and VKORC1 [14,15]. A
recent study furthermore identified a third gene, CYP4F2
explaining about 1.5% of dose variance [16]. However, the genes
accounting for the remaining variability in the response to
warfarin are still unknown.
Other cases of ADRs may arise as a consequence of drug-drug
interactions, or the interplay between the effect of the drug and
environmental factors [9,15]. Indeed, the interaction between
genotype and environment observed in several aspects of health
and disease also extend to drug response and safety. For example,
alcohol consumption and smoking are both associated with
changes in the expression of the metabolic enzyme CYP2E1,
therefore affecting the pharmacokinetics of certain drugs [17].
Challenges in studying ADRs
From the above paragraphs, it is clear that the study of the
molecular and biological mechanisms underlying ADRs requires
achieving a synthesis of information across multiple disciplines. In
particular, it requires the integration of information from a variety
of knowledge domains, ranging from the chemical to the biological
up to the clinical. Different resources cover information about
these different knowledge domains, and many of them are freely
available on the web, such as biological and chemical databases
and the biomedical literature. On the other side, new data is
produced continuously, and the list of resources and published
papers that a researcher interested in ADRs needs to cope with is
turning more into a problem than into a solution. It has been
recognized that the adequate management of knowledge is
becoming a key factor for biomedical research, especially in the
areas that require traversing different disciplines and/or the
integration of diverse and heterogeneous pieces of information
[18]. A key aspect is the integration of heterogeneous data types,
and several authors have discussed the challenges of data
integration in the life sciences [19,20], which are rooted in the
inherent complexity of the biological domain, its high degree of
fragmentation, the data deluge problem, and the widespread
ambiguity in the naming of entities [21]. In addition to the
complexity of extracting, storing and integrating heterogeneous
data from multiple domains one needs to consider the lack of
completeness of the data available [22], an aspect that has a direct
impact on the scope and conclusions of any analysis performed on
the integrated data.
On the other hand, approaching current biomedical research
questions by computational analysis requires a combination of
different methods. An attractive approach that emerged in the last
years is the combination of different bioinformatics analysis
modules by means of pipelines or workflows [23]. This technology
allows the integration of a variety of computational techniques into
a processing pipeline in which the input and outputs are
standardized. This kind of integration has been greatly facilitated
by the use of public APIs and web services allowing programmatic
access to data repositories and analysis tools. The open source
software Taverna is one of such approaches that allow integration
of different analysis modules, shared as web services, into a
scientific workflow to perform in silico experiments [24]. Similar
approaches are also used for the processing of free-text documents
(http://uima.apache.org/) or for combining data mining methods
(http://www.knime.org/).
In this article we present a general framework developed in the
context of the EU-ADR project for a systematic analysis of adverse
drug reactions. The entry point of the system is a potential drug
safety signal, which is composed of the drug and its associated
adverse reaction. In the process of signal filtering, we search for
previous reports of the potential signal in specialized databases and
in the biomedical literature. In the process of signal substantiation, we
seek to provide a plausible biological explanation to the potential
signal. This framework was implemented by means of software
modules accessible through web services and integrated into
workflows ready to be used for automatic filtering and substan-
tiation of drug-event associations. Finally, we present a detailed
analysis of antipsychotic drugs and their association with the
prolongation of the QT interval, as well as a large scale analysis of
drug-side effect pairs from SIDER [25] emphasizing the usefulness
of our signal filtering and substantiation workflows.
Results
A framework for the filtering and substantiation of drug-
event pairs
The here presented framework for the filtering and substanti-
ation of drug safety signals consists of placing the potential signal
Author Summary
Adverse drug reactions (ADRs) constitute a major cause of
morbidity and mortality worldwide. Due to the relevance
of ADRs for both public health and pharmaceutical
industry, it is important to develop efficient ways to
monitor ADRs in the population. In addition, it is also
essential to comprehend why a drug produces an adverse
effect. To unravel the molecular mechanisms of ADRs, it is
necessary to consider the ADR in the context of current
biomedical knowledge that might explain it. Nowadays
there are plenty of information sources that can be
exploited in order to accomplish this goal. Nevertheless,
the fragmentation of information and, more importantly,
the diverse knowledge domains that need to be traversed,
pose challenges to the task of exploring the molecular
mechanisms of ADRs. We present a novel computational
framework to aid in the collection and exploration of
evidences that support the causal inference of ADRs
detected by mining clinical records. This framework was
implemented as publicly available tools integrating state-
of-the-art bioinformatics methods for the analysis of drugs,
targets, biological processes and clinical events. The
availability of such tools for in silico experiments will
facilitate research on the mechanisms that underlie ADR,
contributing to the development of safer drugs.
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in the context of current knowledge of biological mechanisms that
might explain it. Essentially, we are searching for evidence that
supports causal inference of the signal, i.e. feasible paths that
connect the drug with the clinical event of the adverse reaction.
The signal filtering analysis looks for evidence reporting the drug-
event association in the biomedical literature and biomedical
databases. The signal substantiation process considers two
scenarios able to provide a causal inference of the signal (see
Figure 1). First, we look for connections between the drug and the
event through their associated protein profiles. Here, a connection
is established if there are proteins in common between the drug-
target and the event-protein profile (Figure 1A). Many ADRs are
caused by altered drug metabolism for which genetic variants in
metabolizing enzymes are often responsible. Consequently, we
also consider drug metabolism phenomena as an underlying
mechanism of the observed ADR by assessing if the drug
metabolites are targeting proteins that are known to be associated
with the clinical event. Second, the association between the drug
and the clinical event can involve proteins that are not directly
associated with the drug and the clinical event, but indirectly in the
context of biological networks. The final consequence of the drug
action is the observed clinical event. Thus, the proteins in the
drug-target profile and event-protein profile are mapped onto
biological pathways to evaluate if the drug and the event can be
connected through biological pathways (Figure 1B).
Our approaches for signal filtering and signal substantiation were
implemented using dedicated bioinformatics methods that are
accessed through web services and integrated into processing
pipelines by means of Taverna workflows. The substantiation
workflow results can be visualized and analyzed by means of other
bioinformatics tools such as Cytoscape [26], a software for network
visualization and analysis. For the signal filtering process, we have
implemented two Taverna workflows (ADR-FM and ADR-FD)
that access data mined from databases such as DrugBank [27],
DailyMed (http://dailymed.nlm.nih.gov/) and MedlineH. A third
Taverna workflow, (ADR-S), performs the signal substantiation
process and was implemented by combining in silico target
profiling, text mining and pathway analysis, among other
bioinformatics approaches. More details about the implementation
of web services and workflows can be found in the Methods
section.
Antipsychotic drugs and risk of cardiac arrhythmias
In the following section we describe the results of the analysis of
potential drug safety signals as a proof of concept of the here
proposed framework and tools.
In the 1990s, the occurrence of several cases of serious, life-
threatening ventricular arrhythmias and sudden cardiac deaths,
secondary to the use of non-cardiac drugs raised concerns with
regulators [28]. In 1998, several drugs received a black-box
warning in the US due to concerns regarding prolongation of the
QT interval. Nowadays, it is known that many seemingly
unrelated drugs can cause the prolongation of QT interval and
Torsade de Pointes, which eventually may lead to fatal
arrhythmias. For instance, cisapride, a drug for gastrointestinal
protection, was withdrawn from the market in 2000 due to
increased risk for QT prolongation. The first report of sudden
cardiac death with an antipsychotic drug appeared in 1963 [29].
Since then, several studies found an increased risk for ventricular
arrhythmias, cardiac arrest and sudden death associated with the
use of antipsychotics [30], which can partly be explained by the
prolongation of QT intervals observed with several antipsychotic
drugs. It has been suggested that the mechanisms by which
antipsychotics can cause prolongation of QT interval involve the
potassium channel encoded by the KCNH2 gene that regulates
myocyte action potential [31,32]. Drugs blocking this potassium
channel can slow down repolarization, which in turn may lead to
the prolongation of the QT interval, eventually resulting in sudden
cardiac death. We selected six antipsychotic drugs according to
their risk of producing cardiac arrhythmias from [33] and from the
QTdrugs database (http://www.qtdrugs.org) (Tables 1 and 2) and
analyzed their association with the prolongation of the QT interval
as defined in the EU-ADR project (referred to as QTPROL) using
our signal filtering and substantiation workflows. The results of the
filtering analysis (shown in Table 1) indicate that all drug-event
associations are discussed in the literature or recorded in
specialized databases, with the only exception of DrugBank that
does not contain any information on the association of the selected
drugs with QTPROL. When comparing both Medline-based
filtering workflows, ADR-FM/MeSH and ADR-FD/Medline, the
latter appears to be more sensitive as the number of abstracts
found is generally higher (compare columns ADR-FM/MeSH and
ADR-FD/Medline in Table 1). This difference might be explained
by the different methods used by the two approaches. The
MeSHH-based approach uses the MeSH terms assigned to each
citation and the ADR-FD approach uses Natural Language
Processing on title and abstracts to identify drug-event associa-
tions. Both Medline-based approaches can be compared with a
PubMed query (‘‘(QT or QTc) prolongation ,one of the six
antipsychotic drugs.’’), which resulted in 2–3 times more
abstracts being returned than by ADR-FD/Medline. This does
not come as a surprise since PubMed searches for keyword co-
occurrences at the abstract level. The workflows are more specific
since they search at the sentence level (ADR-FD/Medline) or use
additional information provided by the MeSH subheadings and
the use of the pharmacological action (ADR-FM/MeSH). It
should be noted that Medline is only one source of information to
filter known signals; DrugBank and DailyMed are other,
potentially complementary, sources. In the case of pimozide, no
results are obtained from DailyMedH, since QT prolongation is
not mentioned in the adverse reactions section but in the
contraindications and warnings sections.
We furthermore explored the mechanisms underlying the
association between QTPROL and the selected antipsychotics
using the substantiation workflow. The results are summarized in
Table 2 (see Table 3 for a quick reference guide to gene and
protein names discussed throughout the example) and Figure 2,
which shows a detail of the Cytoscape graph representing the
drug-protein-event network resulting from analyzing haloperidol
and its association with QTPROL. For all the antipsychotic drugs,
with the exception of sulpiride, connections are established
through proteins associated with both, drug and event. All the
connections between the drug and the event include the protein
HERG encoded by the KCNH2 gene. All of the found
connections are statistically significant except for ziprasidone (see
Table 3). The high-risk antipsychotics haloperidol, ziprasidone
and pimozide are potent potassium channel blockers (IC50 or Ki
in the 0.1 mM range, Table 2). In the case of ziprasidone, it is
worth to mention that one of the metabolites of the drug is
predicted to bind to the protein HERG. Contrasting, olanzapine
shows a lower activity on the protein HERG, while sulpiride has
no activity on this protein. In addition to HERG, for the high-risk
antipsychotics pimozide and haloperidol the drug and the event
can be connected through the proteins encoded by the genes
KCNH1 and CANCNA1C. In the case of KCNH1, which
encodes the protein hEAG1, the ADR-S workflow provides
evidence indicating that mutations in an animal model showed an
association with prolonged QT interval and cardiac arrhythmia
Filtering and Substantiation of Drug Safety Signals
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Figure 1. Schematic representation of the signal substantiation process. The signal substantiation process involves the automatic search for
evidences that support the causal inference of the potential signal. A. Signal substantiation through proteins. The profile of targets of the drug and its
metabolites is obtained by in silico profiling methods (Drug-Target-Profile). The profile of proteins associated with the clinical event is obtained by
mining DisGeNET (Event-Protein Profile). The profiles are compared to find proteins in common in both profiles (Drug-Event Linking Proteins). The
evidences that support the association of the drug and event with the Drug-Event Linking proteins are explored to determine if they support the
causal inference of the signal. B. Signal substantiation through pathways. Proteins in the Drug-Target-Profile and in the Event-Protein Profile are
searched in The Human Protein Atlas database to determine if they are expressed in the same tissue and cell type. Proteins that share expression at
Filtering and Substantiation of Drug Safety Signals
PLoS Computational Biology | www.ploscompbiol.org 4 April 2012 | Volume 8 | Issue 4 | e1002457
[34]. The mutations in the CACNA1C gene, which encodes the
depolarizing long-lasting calcium current channel, are associated
with Timothy syndrome, characterized by severe prolongation of
the QT interval.
Interestingly, our analysis also indicates that the antipsychotics
in our study have an important activity on adrenergic receptors
(Figure 2 B).
Moreover, haloperidol shows activity on the drug transporter
encoded by the gene ABCB1 (Ki 0.2 mM, Figure 1B). Similar
activities are found for pimozide, whereas ziprasidone, olanza-
pine, sulpiride and quetiapine do not show activity on the
transporter.
Regarding the substantiation through pathways, for haloperidol
and pimozide we found several Reactome pathways (Integration of
energy metabolism, Axon guidance, Synaptic transmission,
Signaling by GPCRs and Diabetes pathways), which connect the
drug and the event, and where the involved proteins are expressed
in cardiac tissues. It is likely that the effect of a drug on its target
proteins will affect proteins in their direct neighborhood in the
biological pathway. Hence, we computed the average shortest
path length between pairs of drug and event associated proteins in
the Reactome pathways and compared them to the average
shortest path length between randomly selected drug and event
proteins. Interestingly, for all five antipsychotic drugs, the drug
and event proteins are in close proximity in the Reactome
pathways with average shortest path lengths between 2 and 3,
which are significantly shorter than the average shortest path
length of 5 of randomly selected drug and event proteins (p-
value,= 0.05).
In summary, the ADR-S workflow provides different
hypotheses explaining the antipsychotics-induced QTPROL,
including the direct action of the drug on proteins associated
with the clinical event (e.g. HERG), the cross-talk between
different biological processes (adrenergic signaling and cardiac
action potential), and the differential distribution of drugs
among tissues (due to inhibition of transporters exerted by the
drug). Moreover, it also highlights several interesting evidences
that might explain the differences between low and high-risk
antipsychotics.
Analysis of drug-event pairs from SIDER
In addition to the example case presented above, the ADR-S
workflow was evaluated on a large-scale data set. The SIDER
database was used to extract drug-event pairs (see Methods). Here,
an event refers to a known side effect of a drug compiled from
package inserts of the drugs from several public sources [25]. For a
total of 28251 drug-event pairs, 6108 (4265 with p-value,= 0.01)
pairs can be directly linked through at least one protein connecting
the drug with the side effect. Interestingly, 2692 (44%) of the
60108 drug-event pairs are connected by means of the drug
metabolites. Moreover, the substantiation through pathways
module finds connections between 21526 pairs (10789 with p-
value,= 0.01). This quantitative analysis should be followed by a
thorough qualitative study on selected drug-event pairs of interest
in order to explore the found connections and derive mechanistic
hypothesis. Hence, we make the results of the analysis available as
Supplementary Material (Dataset S1 and S2).
Discussion
Recent studies highlight the use of disparate data sets in the
study of ADRs, enabled by bioinformatics methodologies.
Combining the study of protein–drug interactions on a structural
proteome-wide scale with protein functional site similarity search,
small molecule screening, and protein–ligand binding affinity
profile analysis, Xie and colleagues [35] have elucidated a
possible molecular mechanism for the previously observed, but
molecularly uncharacterized, side effect of selective estrogen
receptor modulators (SERMs). In another study, the side effect
information from prescription drug labels was exploited to
identify novel molecular activities of existing drugs [25]. The
Unified Medical Language System (UMLS) MetathesaurusH [36]
was used as a vocabulary for the side effects, and a weighting
scheme to account for the rareness and interdependence of side
effects was developed. Since similarity in side effects correlated
with shared targets between drugs, side effect similarity was used
to predict novel targets between any two ‘‘unexpected’’ drug pair
[25]. In another study, Berger and colleagues used a computa-
tional systems biology approach to analyze drug-induced long
both levels (tissue and cell type) are used to query Reactome database, and pathways that contain at least one protein from the Drug-Target-Profile
and one protein from the Event-Protein Profile are retrieved. Then, these pathways are explored to determine if they support the causal inference of
the signal.
doi:10.1371/journal.pcbi.1002457.g001
Table 1. Antipsychotics with low and high risk of producing prolongation of the QT interval (QTPROL) analyzed with the filtering
workflows (ADR-FM and ADR-FD).
Workflow
ADR-FM ADR-FD
Risk of QTPROL Drug Name ATC code MesH Medline DailyMed DrugBank
Low Sulpiride N05AL01 7 6 NA 0
Quetiapine N05AH04 7 18 2 0
Olanzapine N05AH03 14 20 1 0
High Ziprasidone N05AE04 15 38 3 0
Pimozide N05AG02 0 16 0 0
Haloperidol N05AD01 23 55 12 0
For the ADR-FD, the individual results obtained from the three different sources used (Medline, DailyMed and DrugBank) are shown. The table shows the number of
records found in each case. NA: Not Available.
doi:10.1371/journal.pcbi.1002457.t001
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QT syndrome, and showed that the analysis of a human protein
interaction network associated with congenital long QT syn-
drome can be used to predict new gene variants for long QT
syndrome, to explain the complexity of the adverse drug reaction,
and to predict the susceptibility of new drugs to cause long QT
syndrome [32].
All these examples illustrate how computational approaches are
paving the way toward elucidating the molecular mechanisms of
ADRs. The here presented framework follows this direction, by
traversing and integrating information from the chemical domain,
through genes and proteins, molecular and cellular networks, and
finally to the clinical domain. The filtering workflows interrogate
specialized databases and literature repositories in order to
determine the novelty of a drug-event association. On the other
hand, the substantiation framework seeks to find hypotheses that
might explain drug-induced clinical events by looking for
evidences supporting causative connections between the drug, its
targets, and their direct or indirect (through biological pathways)
association to the clinical event. The signal substantiation process
can be framed as a closed knowledge discovery process, analogous
to the Swanson model based on hidden literature relationships
[37], which we extend by considering not only relationships found
in the literature, but also relationships discovered by mining other
data sources or found by applying different bioinformatics
methods (vide infra). For a drug-event association, we collect
information about the drug-targets by querying publicly available
databases and by applying in silico drug-target profiling methods
[38]. In parallel, we retrieve information about the genes and
proteins associated with the clinical event from a database
covering knowledge about the genetic basis of diseases [39].
Then, we combine these two pieces of information under the
following assumption: if the disease phenotype elicited by the drug
is similar to the phenotype observed in a genetic disease, then the
drug acts on the same molecular processes that are altered in the
disease. This can be regarded as phenocopy, a term originally coined
by Goldschmidt in 1935 [40] to describe an individual whose
phenotype, under a particular environmental condition, is
identical to the one of another individual whose phenotype is
determined by the genotype. In other words, in the phenocopy the
environmental condition mimics the phenotype produced by a
Table 2. Antipsychotics with low and high risk of producing prolongation of the QT interval (QTPROL) and the results of the
substantiation process.
Risk of QTPROL Drug Name ATC code Events
Drug-event
linking proteins p-value
Low Sulpiride N05AL01 None None None
Quetiapine N05AH04 LONG QT SYNDROME 1/2, 2, 2/5 and 2/3, TIMOTHY
SYNDROME, Torsades de Pointes, Romano-Ward Syndrome
HERG (KCNH2, pKi 5.24) 0.0190
Olanzapine N05AH03 LONG QT SYNDROME 1/2, 2, 2/5 and 2/3, TIMOTHY
SYNDROME, Torsades de Pointes, Romano-Ward Syndrome
HERG (KCNH2, pKi 4.64,
pIC50 6.18)
0.0190
High Ziprasidone N05AE04 LONG QT SYNDROME 1/2, 2, 2/5 and 2/3, TIMOTHY
SYNDROME, Torsades de Pointes, Romano-Ward Syndrome
HERG (KCNH2, pKi 6.77,
pIC50 6.36)
0.1979
Pimozide N05AG02 LONG QT SYNDROME 1/2, 2/3, 2 and 2/5, TIMOTHY
SYNDROME, Torsades de Pointes, Romano-Ward
Syndrome, cardiac arrhythmia
HERG (KCNH2, pKi 6.99,
pIC50 6.73), Cav1.2
(CACNA1C, pKi 6.7), hEAG1
(KCNH1, pIC50 6.2)
0.0025
Haloperidol N05AD01 LONG QT SYNDROME 2/3, 2, 2/5 and 1/2, TIMOTHY
SYNDROME, Torsades de Pointes, Romano-Ward Syndrome
HERG (KCNH2, pKi 6.99,
pIC50 6.73), Cav1.2
(CACNA1C, pKi 6.7),
hEAG1 (KCNH1, pIC50 6.2)
0.0025
The columns display the risk of producing QTPROL for each drug, the drug name, the ATC code of the drug, the proteins that explain the connection between the drug
and the event (Drug-event linking proteins), the clinical events associated with these proteins (Events), as well as p-values. For the drug-event linking proteins, the
common protein name is given, and the Gene Symbol and the drug activity values of each drug-event linking protein (pKi or pIC50, average of the multiple values from
different sources) are shown in parenthesis.
doi:10.1371/journal.pcbi.1002457.t002
Table 3. List of proteins discussed in the text with their corresponding protein and gene identifiers.
Gene Symbol Approved name (HGCN) Other names
UniProt
Accession
UniProt
Identifier
NCBI Entrez
Gene
KCNH1 potassium voltage-gated channel,
subfamily H (eag-related), member 1
hEAG1, Kv10.1,
eag, eag1, h-eag
O95259 KCNH1_HUMAN 3756
KCNH2 potassium voltage-gated channel,
subfamily H (eag-related), member 2
HERG, Kv11.1, erg1 Q12809 KCNH2_HUMAN 3757
CACNA1C calcium channel, voltage-dependent,
L type, alpha 1C subunit
Cav1.2, CACH2, CACN2, TS Q13936 CAC1C_HUMAN 775
ABCB1 ATP-binding cassette, sub-family B
(MDR/TAP), member 1
Multidrug resistance protein 1,
ABC20, CD243, GP170, P-gp
P08183 MDR1_HUMAN 5243
HGNC: HUGO Gene Nomenclature Committee (http://www.genenames.org/).
doi:10.1371/journal.pcbi.1002457.t003
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gene. In the case of ADRs, the environmental condition is
represented by the exposure to the drug, whose effect mimics the
phenotype (disease) produced by a gene in an individual. In this
way, we can capitalize on all the knowledge about the genetic basis
of diseases to explore mechanisms underlying ADRs.
We illustrate our approach by analyzing a clinically relevant
drug safety signal: prolongation of the QT interval (QTPROL)
leading to cardiac arrhythmias produced by a set of antipsychotic
drugs. The results of the filtering workflows show that the
association of QTPROL with the antipsychotic drugs has been
extensively discussed in the literature and is documented in
specialized databases. On the other hand, the substantiation
workflow provides different hypotheses explaining the antipsy-
chotics-induced QTPROL. First, we were able to confirm the
widely accepted mechanism proposed for drug-induced
QTPROL, in which the drug blocks the potassium channel
HERG (encoded by the KCNH2 gene) and this blockade leads to
a prolongation of the QT interval [41,42]. The known association
of congenital long QT syndrome being associated with mutations
in the KCNH2 gene furthermore supports this concept [38,39].
Interestingly, our analysis reveals that high-risk antipsychotics
show higher activities on the potassium channel than low-risk
antipsychotics (see Table 2), suggesting that the strength of binding
might explain the different risks of observing the side effect for
different antipsychotics. For all except one antipsychotic (ziprasi-
done), the associations between the drugs and QTPROL are
statistically significant (p-value,= 0.01). We want to point out,
that even for ziprasidone with a higher p-value, the evidences
provided by the workflow give enough confidence to establish the
hypothesis of the blockage of HERG being related with
QTPROL. We believe that each drug-event pair and the
evidences provided by the workflows have to be studied carefully
in order to generate hypotheses valid to be tested. We furthermore
find a connection of high-risk antipsychotics and QTPROL
through other proteins different from HERG, suggesting that the
prolongation of the QT interval might result from the effect of the
drugs on other channel proteins regulating the action potential. In
addition to the direct blockade of channels creating ion currents
involved in the action potential, other factors can be considered for
the mechanism of antipsychotics-induced QTPROL. Adrenergic
activation due to stress can precipitate cardiac arrhythmias [35]; in
fact, the main treatment for patients with congenital long QT
syndrome is beta-adrenergic blocking [41]. Alpha and beta-
receptors agonists produce an inhibition of the potassium channel
leading to the prolongation of QT [34]. Interestingly, our results
indicate that the antipsychotics in our study have an important
activity on adrenergic receptors. Haloperidol has been reported to
act as partial agonist in cerebral alpha-adrenergic receptors [43].
Hence, our results suggest that the modulation of adrenergic
signaling by haloperidol might be an additional factor resulting in
the inhibition of the potassium repolarizing current. Thus, in the
case of haloperidol, direct inhibition by the drug combined with an
indirect mechanism involving the activation of beta adrenergic
signaling might lead to HERG blockade. These findings are in line
with evidences supporting the notion that ADRs may often be
caused by the combined action of multiple genes [9].
We furthermore found that activities of haloperidol and
pimozide on the drug transporter encoded by the gene ABCB1
(Ki 0.2 mM, Figure 1B), while ziprasidone, olanzapine, sulpiride
and quetiapine do not show activity on this transporter. Titier and
Figure 2. Cytoscape graph for QTPROL-haloperidol. The results of the ADR-S workflow can be visualized as a graph in which the nodes are
proteins, compounds and clinical events. A: Detail of the network depicting the haloperidol targets, the proteins associated with QTPROL and the
connection between them. The proteins encoded by the genes KCNH1, KCNH2 and CACNA1C constitute Drug-Event linking proteins between
haloperidol and the terms corresponding to QTPROL. B: Detail of the targets of haloperidol, showing the adrenergic receptors (light blue) and the
drug transporter encoded by the gene ABCB1 (purple). In both graphs, the multiple edges between two nodes represent different evidences for the
corresponding association between the nodes.
doi:10.1371/journal.pcbi.1002457.g002
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colleagues studied the myocardium to plasma concentration ratio
of several antipsychotic drugs, reporting ratios of 2.7 for
olanzapine and 6.4 for haloperidol [43]. Therefore, the different
distributions of the antipsychotics between plasma and the heart
could be another factor influencing the varying risk of different
antipsychotic drugs to induce QTPROL.
Regarding the analysis through biological pathways, our
workflow does not provide novel hypotheses that might explain
drug-induced QTPROL in addition to the above presented
hypotheses. Nevertheless, it is interesting that the drug target
proteins and event-associated proteins are closely located in the
Reactome pathways. All in all, a detailed analysis of the generated
paths might add valuable information about the mechanism
underlying the drug adverse reaction. Ultimately, the usefulness of
the pathway module strongly depends on the drug-safety signal of
interest. For example, the cholesterol-lowering drug cerivastatin
was withdrawn from the market in 2001 due to its fatal risk to
induce rhabdomyolysis leading to kidney failure [44]. While the
ADR-S workflow connects cerivastatin and rhabdomyolisis
through proteins and pathways, it only finds a meaningful
connection between the drug and acute renal failure through the
pathway module. Hence, in this example the pathway module
adds valuable information to the analysis. We also want to
mention some limitations of the pathways module. The publicly
available information on pathways is not complete, and the level of
detail differs between the pathways. Moreover, the Reactome
pathways used are at a very high level in the Reactome hierarchy
and can be very general; hence the substantiation results need to
be carefully analyzed in order to determine if the connection found
between the drug and the event represents a plausible explanation
of the ADR.
In summary, using antipsychotics and their risk to induce
QTPROL, we showed that the filtering workflows are able to
extract relevant information from the literature and dedicated
databases. We also showed that the substantiation workflow
provides different hypotheses explaining the antipsychotics-
induced QTPROL. These hypotheses include the direct action
of the drug on proteins associated with the clinical event (e.g.
HERG), the cross-talk between different biological processes
(adrenergic signaling and cardiac action potential), and the
differential distribution of drugs among tissues (due to inhibition
of transporters exerted by the drug). Moreover, the analysis also
highlights several interesting evidences that might explain the
differences between low and high-risk antipsychotics. In addition,
we provide the results of a large-scale analysis of drug-side effect
pairs from SIDER and show that about 22% of the known side
effects of drugs might involve direct effects of drugs on proteins
being associated with the events. This relatively small number is
not surprising because not all drug side effects can be attributed to
the direct action of the drug onto its targets, such as on-target and
off-target pharmacological effects. Other mechanisms of drug
toxicity have been discussed. For example, metabolites can react
with nucleophiles including DNA, which can trigger regulatory
processes leading to inflammation, apoptosis and necrosis [45].
Moreover, the workflow uses public data sources on drug-target
and event-protein associations, which are not complete. Interest-
ingly, almost half (44%) of the direct connections through proteins
involve metabolites of the drugs. This finding is in good agreement
with current opinion on the relevance of drug metabolism for drug
adverse reactions [9]. The pathway module connects many more
drug-side effect pairs. Although, the results of our workflow for
each drug-side effect pair have to be carefully analyzed in detail,
this finding suggests that the indirect connection of drug and event
in the context of biological networks plays an important role. We
want to stress that the substantiation workflow provides a variety of
evidences, such as the binding strength of the drug to its targets, as
well as the provided literature sources supporting the associations
of proteins to the events. All pieces of evidence need to be carefully
considered to generate hypotheses of mechanisms that are valid to
be further tested.
Both filtering and substantiation workflows are available to the
community and allow a systematic and automatic analysis of drug
safety signals detected by mining clinical records, providing a user-
friendly framework for the analysis of drug-event combinations.
We believe that with the availability of such tools for in silico
experimentation, research on the mechanism that underlies drug-
induced adverse reactions will be facilitated, which will have great
impact in the development of safer drugs.
Methods
The signal filtering and substantiation framework has been
implemented by means of software modules that perform specific
tasks of the processes. To allow access and integration of the
modules in high-level analysis pipelines, the modules were
implemented as web services and combined into data processing
workflows to achieve the aforementioned signal filtering and signal
substantiation. To standardize data exchanges between the
different web services, we have developed two complementary
schemas using XSD to define a common XML interoperability
structure. The first one describes general data types (http://
bioinformatics.ua.pt/euadr/common_types.xsd) and the second
one defines the specific types needed for signal filtering and
substantiation in the context of the EU-ADR project (http://
bioinformatics.ua.pt/euadr/euadr_types.xsd). Both schemas allow
a smooth integration of the different modules in Taverna
workflows, by enabling content and structure validation for the
workflow input and output XML files. Moreover, the use of
schemas facilitates further data transformations, for example, by
applying XSL transformation to XML files of the signal
substantiation workflow to create XGMML file graphs that can
be visualized with Cytoscape. The workflows and web services are
described in the following sections. All workflows have been
implemented and tested using Taverna Workflow Management
system version 2.2.
Workflows: Signal filtering
We have implemented two workflows for signal filtering. The
ADR-FM workflow is a MeSHH-based approach to find drug-
event pairs in MedlineH citations. The ADR-FD workflow uses
text-mining to find the drug-event pairs in MedlineH abstracts,
databases such as DrugBank and drug labels available at
DailyMedH.
ADR-FM. The aim of this signal filtering workflow is to
automate the search of publications related to a given drug-
adverse event association. It is based on an approach that uses the
MeSHH annotations of MedlineH citations, in particular the
subheadings ‘‘chemically induced’’, ‘‘adverse effects’’ and
‘‘Pharmacological Action’’ [46]. This workflow offers the
opportunity to automatically determine if an ADR has already
been described in MedlineH. However, the causality relationship
between the drug and an event may be judged only by an expert
reading the full text article and determining if the methodology of
this article was correct and if the association is statically significant,
among other factors. The workflow uses the method getListPublis of
the UB2_EUADR web service (Table 4).
Workflow input. The ADR-FM workflow accepts two
inputs, the ATC (Anatomical Therapeutic Chemical, http://
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www.whocc.no/atc_ddd_index/) code of the drug at the 7 digits
level (e.g. M01AH02 for rofecoxib) and the event represented by a
string as defined in the EU-ADR project (see Table 5).
Workflow output. The workflow returns an XML file and an
HTML page summarizing the results, showing the PubMed
identifiers of the retrieved citations grouped by publication type. A
chart of the number of retrieved citations per year is generated
using Google Charts Tools (http://code.google.com/apis/chart/).
ADR-FD. This workflow looks for associations between drugs
and side effects that have been recorded in literature (MedlineH) or
in databases (DailyMedH and Drugbank). These resources have
been indexed, and co-occurrences of drugs (corresponding to ATC
codes) and side effects as defined in the EU-ADR project were
captured and stored in a database. Briefly, all abstracts in the
Medline database were split into sentences, and all sentences were
indexed by the concept-recognition tool Peregrine [47] to find
drugs and adverse events. A chi-square test was performed to
check if the probability of the drug and the adverse event co-
occurring together in a sentence was significantly different than
would be expected by chance. Regarding the databases, for each
entry in DrugBank a field specifying ATC codes and a field
listing potential adverse events were extracted and processed by
Peregrine. DailyMedH contains Summary Product Characteristics
(SPCs) of drugs. Each SPC was parsed to extract the ‘‘title’’ field
(containing the drug name) and the ‘‘adverse reaction’’ and
‘‘boxed warning’’ fields (containing the adverse events). These
fields were subsequently indexed by Peregrine and the output was
processed to link ATC codes to UMLS concept identifiers of
adverse events. The workflow uses the method get FilteredRelations
(Table 4), which provides relationships between a drug and an
event in one or more of the data sources.
Workflow input. The ADR-FD workflow accepts three
inputs: the ATC code of the drug at the 7-digit level (e.g.,
M01AH01 for celecoxib), the event as defined in the EU-ADR
project (Table 5), and the data resources in which the specified
drug-event pair is sought (MedlineH, DailyMedH, or DrugBank).
Workflow output. The output of the workflow consists of a
list of links to entries in the input data sources (MedlineH abstracts,
DailyMedH SPCs, or Drugbank cards) in which the input drug-
event association is mentioned. The output is generated in XML
format and in HTML format.
Workflows: Signal substantiation
ADR-S. The ADR substantiation (ADR-S) workflow seeks to
establish a connection between the clinical event and the drug
through (i) proteins targeted by the drug (or by its metabolites) and
associated with the clinical event and (ii) biological pathways. In
the first connecting path, the link between the drug and the event
is established through the set of proteins in common between the
Drug-Target-Profile and the Event-Protein-Profile (Figure 1A). In
the second path, the link is established through a set of proteins
that are part of the same biological pathway (Figure 1B). For
example, consider a protein A targeted by the drug and a protein
B associated with the clinical event, and both proteins A and B are
part of the same biological pathway C. Then, the drug and the
event are connected through biological pathway C (see more
details in the description of the service adrPathService). Two SOAP
web services (cglService and adrPathService) allowing access to
databases and bioinformatics modules relevant for the signal
substantiation have been implemented (Table 4). A tutorial
describing how to use the ADR-S workflow can be found in the
Supportive information (Protocol S1) and at http://ibi.imim.es/
ADR_Substantiation.html.
getSmileFromATC (cglAlertService). This method accepts
as input a drug encoded by the ATC code at the 7-digits level and
provides as output the chemical structure by means of SMILE
(Simplified Molecular Input Line Entry Specification).
getUniprotListFromSmile (cglAlertService). This method
accepts as input a drug or metabolite encoded by a SMILE and
returns a list of proteins that are related to the drug (Drug-Target-
Profile). We use known drug-target associations (Table 6) and
extend them with in silico target profiling methods [38]. Drug
metabolites are obtained from a commercial database (GVK
Biosciences) and are also processed by in silico target profiling. The
evidences that support each drug-target relationship, such as the
binding affinity of the compound to the protein or the source
database, are provided.
getDiseaseAssociatedProteins (adrPathService). This method
accepts as input a clinical event (encoded as a list of UMLSH
concept identifiers or as a string as defined in Table 5) and
returns a list of proteins associated to the event (Event-Protein-
Profile), by interrogating the DisGeNET database [39].
Evidences that support each association, including the
association type, source database, publications discussing the
association, and in the case of text-mining derived associations,
the sentence that reports the gene-disease association, are
provided.
getPathways (adrPathService). This method assesses if
proteins associated with the drug and the event are annotated to
the same biological pathway by interrogating Reactome [48]. In
Table 4. Availability of web services and workflows.
URL Description Type
http://bioinformatics.ua.pt/euadr/common_types.xsd XSD schema defining common data types. XSD schema
http://bioinformatics.ua.pt/euadr/euadr_types.xsd XSD schema defining specific types used in the EU-ADR project. XSD schema
http://lesim.isped.u-bordeaux2.fr/axis2/services/UB2_EUADR?wsdl Web service with the method getListPublis Web service endpoint
http://aneurist.erasmusmc.nl/euadr-manager-db/euadr-service-db?wsdl Web service with the method get FilteredRelations Web service endpoint
http://cgl.imim.es/axis2/services/cglAlertService?wsdl Web service with the methods getSmileFromATC and
getUniprotListFromSmile
Web service endpoint
http://ibi.imim.es/axis2/services/AdrPathService?wsdl Web service with the methods getDiseaseAssociatedProteins
andgetPathways
Web service endpoint
http://www.myexperiment.org/workflows/2280.html ADR-FM workflow Workflow
http://www.myexperiment.org/workflows/2279.html ADR-FD workflow Workflow
http://www.myexperiment.org/workflows/1988.html ADR-S workflow Workflow
doi:10.1371/journal.pcbi.1002457.t004
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general, pathway databases such as Reactome contain a canonical,
general description of biological processes and pathways [49]. These
pathways can be found in different cell types and tissues, or in
different time points in the life of an organism; however, not all the
pathway components might be active in all circumstances.
Combining information from pathways with protein expression in
tissues and cell types can result in a cell and tissue type specific view
of a given pathway. Thus, this method combines annotation of
proteins to pathways with information of protein expression in cells
and tissues. Briefly, we determine if the proteins associated with the
drug and the event are expressed in the same tissue and cell type
according to the The Human Protein Atlas version 7.1 [50]. Only
the proteins that share expression at both levels (tissue and cell type)
are kept for the next step. Then, for this list of proteins, we retrieve
all annotations to pathways using the Reactome web service
(Figure 1B). The input of the method is composed of two lists of
UniProt identifiers and the output is an XML document listing the
pathways, the annotated proteins and their expression profile.
Workflow input. The substantiation workflow has five input
ports, called atc, event, eventType, eventName, and cytoscape. The signal
is represented by the ATC code of the drug at the 7-digits level
(e.g. M01AH02 for celecoxib) and the event, which is defined by
the three input ports event, eventName and eventType. We allow two
different types of event definitions: events as defined in the EU-
ADR project (Table 5), and events defined by a set of UMLSH
concept identifiers. The input port eventType is then used to
distinguish between the two definitions for events. The eventName
can be set by the user and is only required for user-friendly
visualization of the results. The cytoscape input port defines the
location of the local Cytoscape installation (e.g. /home/user/
cytoscape-v2.7.0); it is optional and only required for the
visualization of the signal substantiation results (Figure 2).
Workflow output. The output of the signal substantiation
workflow consists of 7 ports representing different layers of the
results. Besides the raw outputs from the individual web services
(drugTargetOutput and diseaseProteinOutput), the protein profile of the
drug or its metabolites (drugTargets), and the protein profile of the
event (diseaseProteins) are provided. The signal substantiation
workflow combines two ways of connecting drug and event,
through proteins or through biological pathways. The outcome of
these results is shown to the user during workflow execution by pop-
up windows. The list of connecting proteins, that is, the protein
annotated to both the drug and the event is provided
(connectingProteins). For a user-friendly visualization and analysis of
the results, a Cytoscape graph (CytoscapeResultGraph) is generated. The
Table 6. Drug-target databases used in the ADR-S workflow.
Database Description URL
AffinDB The Affinity Database (AffinDB) contains affinity data for protein-ligand complexes of the PDB. http://pc1664.pharmazie.uni-marburg.de/affinity/
BindingDB BindingDB is a public, web-accessible database of measured binding affinities for
biomolecules, genetically or chemically modified biomolecules, and synthetic compounds.
http://www.bindingdb.org/bind/index.jsp
ChemblDB ChEMBL is a database of bioactive drug-like small molecules, it contains 2-D structures,
calculated properties (e.g. logP, Molecular Weight, Lipinski Parameters, etc.) and
abstracted bioactivities (e.g. binding constants, pharmacology and ADMET data).
https://www.ebi.ac.uk/chembl/
DrugBank DrugBank is a unique bioinformatics and chemoinformatics resource that combines
detailed drug (i.e. chemical, pharmacological and pharmaceutical) data with
comprehensive drug target (i.e. sequence, structure, and pathway) information.
http://www.drugbank.ca/
hGPCRlig hGPCRlig is a bank of 3-D human G-Protein Coupled Receptor models and their known ligands. http://cheminfo.u-strasbg.fr:8080/hGPCRlig
IUPHARdb IUPHARdb incorporates detailed pharmacological, functional and pathophysiological
information on G Protein-Coupled Receptors, Voltage-Gated Ion Channels, Ligand-Gated
Ion Channels and Nuclear Hormone Receptors.
http://www.iuphar-db.org/index.jsp
MOAD Binding MOAD’s goal is to be the largest collection of well resolved protein crystal structures
with clearly identified biologically relevant ligands annotated with experimentally determined
binding data extracted from literature.
http://www.bindingmoad.org/
NRacl NRacl is an annotated compound library directed to nuclear receptors as a means for
integrating the chemical and biological data being generated within this family. All data
incorporated in NRacl were collected from public sources of information, mainly reviews
and medicinal chemistry journals of the last 10 years [53].
[53]
PDSP This service provides screening of novel psychoactive compounds for pharmacological and
functional activity at cloned human or rodent CNS receptors, channels, and transporters.
http://pdsp.med.unc.edu/indexR.html
PubChem PubChem provides information on the biological activities of small molecules. It is a
component of NIH’s Molecular Libraries Roadmap Initiative.
http://pubchem.ncbi.nlm.nih.gov/
doi:10.1371/journal.pcbi.1002457.t006
Table 5. Event codes and names of events as defined in the
EU-ADR project [48,49].
Event code Event name
BE Bullous Eruptions
AS Anaphylactic Shock
ARF Acute Renal Failure
AMI Acute Myocardial Infarction
ALI Acute Liver Injury
CARDFIB Cardiac Valve Fibrosis
UGIB Upper gastrointestinal bleeding
RHABD Rhabdomyolysis
PANCYTOP Aplastic anemia/Pancytopenia
NEUTROP Neutropenia/Agranulocytosis
QTPROL QT Prolongation
doi:10.1371/journal.pcbi.1002457.t005
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graph is composed of three types of nodes: drug, event, and proteins,
and two types of edges: drug-protein, protein-event. The attributes of
the edges contain supporting information for each association, such
as source databases, association type, binding value for the drug, etc.
(Tables 7 and 8). As result of the pathway analysis the output port
connectingPathways provides a list of all pathways connecting drug and
event that can be visualized as HTML file.
Workflow run. The different web services run in parallel.
The drug ATC code is first processed by the module
getSmileFromATC, which returns the SMILE code of the drug.
The SMILE code is then further processed by the module
getUniprotListFromSmile, which returns the relationships
between the drug and its targets, including targets of the
metabolites of the drug. The event is processed by the module
getDiseaseAssociatedProteins, which returns relationships between
the event and associated proteins. The lists of proteins associated
with drug or event are extracted by means of Java scripts using
XPath queries and are further processed to remove duplicates.
The module ConvertToCytoscapeGraph converts the output of
the web services to a Cytoscape graph for user-friendly
visualization by means of XSL transformation. For the signal
substantiation through proteins, the two protein profiles are
combined to determine the proteins in common between the two
profiles (module CheckIntersection). For the signal substantiation
through pathways, the two protein profiles are subjected to the
module getPathways, which returns a list of pathways to which at
least one drug and one event protein that are expressed in the
same tissue are annotated to. The output is further processed by
module ConvertToHTML, which generates an HTML file listing
the pathways that connect the drug and the event.
Analysis of drug-side effects from SIDER
A dataset of drug-side effects was downloaded from SIDER
(December 2011) [25]. We restricted the SIDER dataset of total
61102 drug-event associations to 28251 associations between 492
drugs and 974 side effects by (i) mapping the used drug and event
identifiers to the vocabularies used in our framework (ATC codes
for drugs and UMLS concept identifiers for adverse events), and
(ii) restricting to drugs and events for which protein annotations
were available. P-values were computed using Fisher exact test and
FDR was used to correct for multiple hypothesis testing.
Shortest path analysis
We used the protein-protein interaction representation of the
Reactome pathways (http://www.reactome.org/download/
current/homo_sapiens.interactions.txt.gz, January 2012) to calcu-
Table 7. Node attributes in the Cytoscape graph.
Entity ID SMILE styleName nodeType
Drug Internal identifier for the node in the network. The SMILE string corresponding
to the drug structure.
Common name for the node. Drug
The ATC code for the drug. The generic drug name.
Metabolite Internal identifier for the node in the network. Not provided Common name for the node. Drug
Internal identifier for the metabolite. Numbered metabolite.
Event Internal identifier for the node in the network. Not applicable Common name for the node. Event
The UMLSH CUI for the event. Name of the UMLSH CUI
concept extracted from UMLSH.
Protein Internal identifier for the node in the network. Not applicable Common name for the node Protein
The UniProt accession number for the protein. Gene symbol for the protein
as in UniProt.
doi:10.1371/journal.pcbi.1002457.t007
Table 8. Edge attributes in the Cytoscape result graph.
ID bindingValue evidenceLink evidenceSource evidenceType relationshipType
Drug-protein Internal identifier
constructed of the ATC
code of the drug and
the UniProt identifier
of the protein.
The binding affinity
value as reported in
the original database.
Not applicable Database providing
the association.
OBSERVATIONAL for
associations taken from
databases. SIMILARITY for
associations from in silico
profiling.
BINDS for
drug-target
binding
Metabolite-
protein
Internal identifier
constructed of the
metabolite identifier
and the UniProt
identifier for
the protein.
The binding affinity
value as reported in
the original database
or transferred during
in silico profiling.
Not applicable Database providing
the association.
OBSERVATIONAL for
associations taken from
databases. SIMILARITY for
associations from in silico
profiling.
BINDS for
metabolite-target
binding.
Event-protein Internal identifier
constructed of the
UMLSH CUI concept
and the UniProt
identifier of the protein.
Not applicable PubMed identifier
of the publication
supporting the
association, empty
if not available.
Database providing
the association.
OBSERVATIONAL for
associations from curated
databases. TEXT-MINING for
text-mining derived
associations.
Association type
according to the
gene-disease
association ontology
available in [23].
doi:10.1371/journal.pcbi.1002457.t008
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late the shortest path between any pair of antipsychotic drug
and QTPROL associated proteins. For this purpose, we
used the implementation of the Dijkstra algorithm in the Perl
package Graph (http://search.cpan.org/,jhi/Graph-0.94/lib/
Graph.pod). We then computed the average shortest path length
for randomly chosen combinations of drug and event proteins and
used a one-sided t-test to assess if the shortest path between the
drug and event proteins as observed in our analysis was shorter
than compared to random.
Event definition and terminology mapping
The EU-ADR project focuses on a selection of adverse drug
reactions that are monitored in electronic health records and
further analyzed by the filtering and substantiation workflows
[7,8]. These events were defined in terms of UMLS Metathesaur-
usH concept identifiers as described in [51,52]. The event codes
and names as defined in the EU-ADR project are listed in Table 5.
The mapping of events codes or strings to UMLS MetathesaurusH
concept identifiers and other vocabularies such MeSHH and
OMIM is implemented within the web services. The ADR-S
workflow accepts events as defined in the EU-ADR project or any
other clinical event defined by UMLS concept identifier. The
UMLS concept identifiers are processed to map them to MeSHH
and OMIM identifiers using the UMLS MetathesaurusH.
Availability
The availability of web services and workflows presented in this
work is detailed in Table 4.
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